198 related articles for article (PubMed ID: 34677610)
1. C3 glomerulopathy associated with monoclonal gammopathy: impact of chronic histologic lesions and beneficial effects of clone-targeted therapies.
Caravaca-Fontán F; Lucientes L; Serra N; Cavero T; Rodado R; Ramos N; Gonzalez F; Shabaka A; Cabello V; Huerta A; Pampa-Saico S; Gutiérrez E; Quintana LF; López-Rubio ME; Draibe J; Alonso Titos J; Fernández-Juárez G; Goicoechea de Jorge E; Praga M
Nephrol Dial Transplant; 2022 Oct; 37(11):2128-2137. PubMed ID: 34677610
[TBL] [Abstract][Full Text] [Related]
2. C3 glomerulopathy associated with monoclonal Ig is a distinct subtype.
Ravindran A; Fervenza FC; Smith RJH; Sethi S
Kidney Int; 2018 Jul; 94(1):178-186. PubMed ID: 29729982
[TBL] [Abstract][Full Text] [Related]
3. Both Monoclonal and Polyclonal Immunoglobulin Contingents Mediate Complement Activation in Monoclonal Gammopathy Associated-C3 Glomerulopathy.
Chauvet S; Roumenina LT; Aucouturier P; Marinozzi MC; Dragon-Durey MA; Karras A; Delmas Y; Le Quintrec M; Guerrot D; Jourde-Chiche N; Ribes D; Ronco P; Bridoux F; Fremeaux-Bacchi V
Front Immunol; 2018; 9():2260. PubMed ID: 30333829
[TBL] [Abstract][Full Text] [Related]
4. Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy.
Chauvet S; Frémeaux-Bacchi V; Petitprez F; Karras A; Daniel L; Burtey S; Choukroun G; Delmas Y; Guerrot D; François A; Le Quintrec M; Javaugue V; Ribes D; Vrigneaud L; Arnulf B; Goujon JM; Ronco P; Touchard G; Bridoux F
Blood; 2017 Mar; 129(11):1437-1447. PubMed ID: 28069603
[TBL] [Abstract][Full Text] [Related]
5. Validation of a Histologic Scoring Index for C3 Glomerulopathy.
Caravaca-Fontán F; Trujillo H; Alonso M; Díaz-Encarnación M; Cabello V; Ariceta G; Quintana LF; Marco H; Barros X; Ramos N; Rodríguez-Mendiola N; Cruz S; Fernández-Juárez G; Rodríguez E; de la Cerda F; Pérez de José A; López I; Fernández L; Pérez Gómez V; Ávila A; Bravo L; Lumbreras J; Allende N; Sanchez de la Nieta MD; Olea T; Melgosa M; Huerta A; Miquel R; Mon C; Fraga G; de Lorenzo A; Draibe J; González F; Shabaka A; Illescas ML; Calvo C; Oviedo V; Da Silva I; Goicoechea de Jorge E; Caravaca F; Praga M;
Am J Kidney Dis; 2021 May; 77(5):684-695.e1. PubMed ID: 33359150
[TBL] [Abstract][Full Text] [Related]
6. Kidney Transplantation in Patients With Monoclonal Gammopathy of Renal Significance (MGRS)-Associated Lesions: A Case Series.
Heybeli C; Alexander MP; Bentall AJ; Amer H; Buadi FK; Dean PG; Dingli D; Dispenzieri A; El Ters M; Gertz MA; Issa NS; Kapoor P; Kourelis T; Kukla A; Kumar S; Lacy MQ; Lorenz EC; Muchtar E; Murray DL; Nasr SH; Prieto M; Rajkumar SV; Schinstock CA; Stegall MD; Warsame R; Leung N
Am J Kidney Dis; 2022 Feb; 79(2):202-216. PubMed ID: 34175375
[TBL] [Abstract][Full Text] [Related]
7. A 78-Year-Old Man with Chronic Kidney Disease and Monoclonal Gammopathy Who Developed Post-Transplant C3 Glomerulopathy - Recurrence or De Novo? A Case Report and Literature Review.
Ruiz-Fuentes MC; Caba-Molina M; Polo-Moyano A; Palomares-Bayo M; Galindo-Sacristan P; De Gracia-Guindo C
Am J Case Rep; 2023 Jun; 24():e939726. PubMed ID: 37329130
[TBL] [Abstract][Full Text] [Related]
8. An update to the pathogenesis for monoclonal gammopathy of renal significance.
Zuo C; Zhu Y; Xu G
Crit Rev Oncol Hematol; 2020 May; 149():102926. PubMed ID: 32199132
[TBL] [Abstract][Full Text] [Related]
9. C3 Glomerulopathy: Ten Years' Experience at Mayo Clinic.
Ravindran A; Fervenza FC; Smith RJH; De Vriese AS; Sethi S
Mayo Clin Proc; 2018 Aug; 93(8):991-1008. PubMed ID: 30077216
[TBL] [Abstract][Full Text] [Related]
10. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome.
Iatropoulos P; Noris M; Mele C; Piras R; Valoti E; Bresin E; Curreri M; Mondo E; Zito A; Gamba S; Bettoni S; Murer L; Fremeaux-Bacchi V; Vivarelli M; Emma F; Daina E; Remuzzi G
Mol Immunol; 2016 Mar; 71():131-142. PubMed ID: 26895476
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up including extensive complement analysis of a pediatric C3 glomerulopathy cohort.
Michels MAHM; Wijnsma KL; Kurvers RAJ; Westra D; Schreuder MF; van Wijk JAE; Bouts AHM; Gracchi V; Engels FAPT; Keijzer-Veen MG; Dorresteijn EM; Volokhina EB; van den Heuvel LPWJ; van de Kar NCAJ
Pediatr Nephrol; 2022 Mar; 37(3):601-612. PubMed ID: 34476601
[TBL] [Abstract][Full Text] [Related]
12. Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents.
Holle J; Berenberg-Goßler L; Wu K; Beringer O; Kropp F; Müller D; Thumfart J
Pediatr Nephrol; 2018 Dec; 33(12):2289-2298. PubMed ID: 30238151
[TBL] [Abstract][Full Text] [Related]
13. Three cases of monoclonal gammopathy of renal significance after kidney transplantation. De novo C3 glomerulopathy.
Serra N; Facundo C; Canal C; Arce Y; Ayasreh N; Vila A; Bardají B; Silva I; López V; Benito S; Ballarín J; Guirado L
Nefrologia (Engl Ed); 2019; 39(2):198-201. PubMed ID: 29914760
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal immunoglobulin mediates complement activation in monoclonal gammopathy associated-C3 glomerulonephritis.
Li LL; Li ZY; Wang SX; Yu XJ; Tan Y; Wang Y; Yu F; Zhao MH
BMC Nephrol; 2019 Dec; 20(1):459. PubMed ID: 31823738
[TBL] [Abstract][Full Text] [Related]
15. Outcome of C3 glomerulopathy patients: largest single-centre experience from South Asia.
Kumar A; Nada R; Ramachandran R; Rawat A; Tiewsoh K; Das R; Rayat CS; Gupta KL; Vasishta RK
J Nephrol; 2020 Jun; 33(3):539-550. PubMed ID: 31820418
[TBL] [Abstract][Full Text] [Related]
16. C3 nephritic factor associated with C3 glomerulopathy in children.
Nicolas C; Vuiblet V; Baudouin V; Macher MA; Vrillon I; Biebuyck-Gouge N; Dehennault M; Gié S; Morin D; Nivet H; Nobili F; Ulinski T; Ranchin B; Marinozzi MC; Ngo S; Frémeaux-Bacchi V; Pietrement C
Pediatr Nephrol; 2014 Jan; 29(1):85-94. PubMed ID: 24068526
[TBL] [Abstract][Full Text] [Related]
17. An update to the pathogenesis for monoclonal gammopathy of renal significance.
Zuo C; Zhu Y; Xu G
Ann Hematol; 2020 Apr; 99(4):703-714. PubMed ID: 32103323
[TBL] [Abstract][Full Text] [Related]
18. Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis.
Michels MAHM; van de Kar NCAJ; van Kraaij SAW; Sarlea SA; Gracchi V; Engels FAPT; Dorresteijn EM; van der Deure J; Duineveld C; Wetzels JFM; van den Heuvel LPWJ; Volokhina EB
Front Immunol; 2021; 12():715704. PubMed ID: 34456924
[TBL] [Abstract][Full Text] [Related]
19. Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan.
Podos SD; Trachtman H; Appel GB; Bomback AS; Dixon BP; Wetzels JFM; Cook HT; Parikh SV; Pickering MC; Tumlin J; Langman CB; Lightstone L; Sperati CJ; Daina E; Bouman KP; Rice K; Thanassi JA; Huang M; Nester C; Remuzzi G
Am J Nephrol; 2022; 53(10):675-686. PubMed ID: 36404708
[TBL] [Abstract][Full Text] [Related]
20. Defining the complement biomarker profile of C3 glomerulopathy.
Zhang Y; Nester CM; Martin B; Skjoedt MO; Meyer NC; Shao D; Borsa N; Palarasah Y; Smith RJ
Clin J Am Soc Nephrol; 2014 Nov; 9(11):1876-82. PubMed ID: 25341722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
